Opinion
Newer IL-17 inhibitors make their case in phase 3 nonradiographic axial spondyloarthritis trials
There appears to be very little to favor either ixekizumab or secukinumab over the other.
Nigil Haroon, MD, PhD
There appears to be very little to favor either ixekizumab or secukinumab over the other.